Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects
Launched by ONO PHARMA USA INC · Jul 27, 2011
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy non-smoking male or female subjects (18-55 inclusive)
- • Body mass index (BMI)of 10-35 kg/m2 (inclusive)
- • For females; postmenopausal, non-lactating, and non-pregnant
- Exclusion Criteria:
- • History or presence of clinical significant disease
About Ono Pharma Usa Inc
Ono Pharma USA Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions that address unmet medical needs. As a subsidiary of Ono Pharmaceutical Co., Ltd., based in Japan, the company leverages a robust pipeline of novel drug candidates across various therapeutic areas, including oncology, immunology, and central nervous system disorders. With a commitment to advancing healthcare through cutting-edge science and collaboration, Ono Pharma USA Inc. strives to improve patient outcomes and enhance quality of life globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miramar, Florida, United States
Patients applied
Trial Officials
Ono Pharma USA, Inc.
Study Director
Ono Pharmaceutical Co. Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials